Comparative Pharmacology
Head-to-head clinical analysis: NUCYNTA ER versus SUBLIMAZE PRESERVATIVE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NUCYNTA ER versus SUBLIMAZE PRESERVATIVE FREE.
NUCYNTA ER vs SUBLIMAZE PRESERVATIVE FREE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tapentadol is a mu-opioid receptor agonist and norepinephrine reuptake inhibitor, providing analgesic effects through opioid receptor activation and modulation of descending pain pathways.
Fentanyl is a potent synthetic opioid agonist with primary action at the mu-opioid receptor. It induces analgesia, sedation, and respiratory depression by activating G-protein-coupled receptors that inhibit adenylyl cyclase, reduce cAMP production, and modulate ion channels (e.g., potassium efflux, calcium influx).
100 mg orally every 12 hours, titrated from 50 mg every 12 hours; maximum 200 mg every 12 hours.
IV: 0.5-2 mcg/kg bolus, may repeat q2-4h; or 0.5-1 mcg/kg/h infusion; IM: 0.5-2 mcg/kg q1-2h prn.
None Documented
None Documented
Terminal elimination half-life: 4.1 hours (range 3.3–4.7 h) after single oral dose; steady state: 4.4 h. No clinically relevant accumulation.
Terminal elimination half-life is 3-7 hours (mean 4.5 h) after IV administration, but may be prolonged (up to 12-15 h) in elderly, hepatic impairment, or after prolonged infusion due to redistribution.
Renal: 99% (tapentadol and glucuronide conjugates); Fecal: <1%; unchanged tapentadol: <5%.
Primarily renal: fentanyl and its metabolites are excreted in urine (~75%) and feces (~9%). Less than 10% excreted unchanged.
Category C
Category C
Opioid Analgesic
Opioid Analgesic